Special Issue "Polycystic Ovary Syndrome"

A special issue of Medical Sciences (ISSN 2076-3271). This special issue belongs to the section "Endocrinology and Metabolic Diseases".

Deadline for manuscript submissions: closed (30 May 2019).

Special Issue Editors

Guest Editor
Dr. Kirsty Walters

Head, Ovarian Biology Laboratory, School of Women’s & Children’s Health, Discipline of Obstetrics & Gynaecology, University of New South Wales, Sydney, NSW 2052, Australia
Website | E-Mail
Interests: Androgens; female fertility; PCOS
Guest Editor
Prof. David Handelsman

Director, ANZAC Research Institute, University of Sydney
Head, Andrology Department, Concord Hospital, Sydney NSW 2139, Australia
Website | E-Mail
Interests: Andrology, Reproductive Endocrinology, Androgen Physiology Pharmacology & Toxicology

Special Issue Information

Dear Colleagues,

Polycystic ovary syndrome (PCOS) affects >100 million women worldwide and is characterized by reproductive, metabolic, and endocrine disturbances. In addition, mounting evidence from human and animal studies implies that adverse PCOS health traits can be transferred to offspring. The high prevalence and wide range of adverse health conditions associated with PCOS brings an urgent challenge—to address not only the infertility, but also to ameliorate the metabolic disorders and intergenerational transmission of PCOS-related ill-health. Recent advances have included consensus international evidence-based guidelines for the assessment and management of PCOS aiming to unify and improve the care and health of women with PCOS. However, as the origin of PCOS remains unknown, there is neither cure nor specific treatment. Hence, there is a pressing need to develop targeted evidence-based treatments for PCOS, but this requires a much deeper knowledge of the physiological mechanisms underpinning its evolution.

This Special Issue will feature short, focused reviews discussing the distinctive features and comorbidities associates with PCOS, the modern evidence-based clinical assessment and management of PCOS, lessons learned from PCOS animal models, and the latest novel ideas in the pathophysiology of PCOS. This Special Issue aims to provide an update on advances and challenges in the field of PCOS. The goal is to provide up-to-date information on new and developing ideas on the origins, diagnosis, and management of PCOS, highlighting the latest concepts in understanding the etiology of PCOS, while also generating thought-provoking directions for future investigations and management.

Dr. Kirsty Walters
Prof. David Handelsman
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medical Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (7 papers)

View options order results:
result details:
Displaying articles 1-7
Export citation of selected articles as:

Review

Open AccessReview
Origins and Impact of Psychological Traits in Polycystic Ovary Syndrome
Med. Sci. 2019, 7(8), 86; https://doi.org/10.3390/medsci7080086
Received: 3 June 2019 / Revised: 25 July 2019 / Accepted: 31 July 2019 / Published: 5 August 2019
PDF Full-text (523 KB) | HTML Full-text | XML Full-text
Abstract
Women with polycystic ovary syndrome (PCOS) exhibit compromised psychiatric health. Independent of obesity, women with PCOS are more susceptible to have anxiety and depression diagnoses and other neuropsychiatric disorders. During pregnancy women with PCOS display high circulating androgen levels that may cause prenatal [...] Read more.
Women with polycystic ovary syndrome (PCOS) exhibit compromised psychiatric health. Independent of obesity, women with PCOS are more susceptible to have anxiety and depression diagnoses and other neuropsychiatric disorders. During pregnancy women with PCOS display high circulating androgen levels that may cause prenatal androgen exposure affecting the growing fetus and increasing the risk of mood disorders in offspring. Increasing evidence supports a non-genetic, maternal contribution to the development of PCOS and anxiety disorders in the next generation. Prenatal androgenized rodent models reflecting the anxiety-like phenotype of PCOS in the offspring, found evidence for the altered placenta and androgen receptor function in the amygdala, together with changes in the expression of genes associated with emotional regulation and steroid receptors in the amygdala and hippocampus. These findings defined a previously unknown mechanism that may be critical in understanding how maternal androgen excess can increase the risk of developing anxiety disorders in daughters and partly in sons of PCOS mothers. Maternal obesity is another common feature of PCOS causing an unfavorable intrauterine environment which may contribute to psychiatric problems in the offspring. Whether environmental factors such as prenatal androgen exposure and obesity increase the offspring’s susceptibility to develop psychiatric ill-health will be discussed. Full article
(This article belongs to the Special Issue Polycystic Ovary Syndrome)
Figures

Figure 1

Open AccessReview
The Role of the Brain in the Pathogenesis and Physiology of Polycystic Ovary Syndrome (PCOS)
Med. Sci. 2019, 7(8), 84; https://doi.org/10.3390/medsci7080084
Received: 7 June 2019 / Revised: 25 July 2019 / Accepted: 30 July 2019 / Published: 2 August 2019
PDF Full-text (641 KB) | HTML Full-text | XML Full-text
Abstract
Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder, affecting at least 10% of women of reproductive age. PCOS is typically characterized by the presence of at least two of the three cardinal features of hyperandrogenemia (high circulating androgen levels), oligo- or [...] Read more.
Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disorder, affecting at least 10% of women of reproductive age. PCOS is typically characterized by the presence of at least two of the three cardinal features of hyperandrogenemia (high circulating androgen levels), oligo- or anovulation, and cystic ovaries. Hyperandrogenemia increases the severity of the condition and is driven by increased luteinizing hormone (LH) pulse secretion from the pituitary. Indeed, PCOS women display both elevated mean LH levels, as well as an elevated frequency of LH pulsatile secretion. The abnormally high LH pulse frequency, reflective of a hyperactive gonadotropin-releasing hormone (GnRH) neural circuit, suggests a neuroendocrine basis to either the etiology or phenotype of PCOS. Several studies in preclinical animal models of PCOS have demonstrated alterations in GnRH neurons and their upstream afferent neuronal circuits. Some rodent PCOS models have demonstrated an increase in GnRH neuron activity that correlates with an increase in stimulatory GABAergic innervation and postsynaptic currents onto GnRH neurons. Additional studies have identified robust increases in hypothalamic levels of kisspeptin, another potent stimulator of GnRH neurons. This review outlines the different brain and neuroendocrine changes in the reproductive axis observed in PCOS animal models, discusses how they might contribute to either the etiology or adult phenotype of PCOS, and considers parallel findings in PCOS women. Full article
(This article belongs to the Special Issue Polycystic Ovary Syndrome)
Figures

Figure 1

Open AccessReview
Developmental Programming of PCOS Traits: Insights from the Sheep
Med. Sci. 2019, 7(7), 79; https://doi.org/10.3390/medsci7070079
Received: 30 May 2019 / Revised: 2 July 2019 / Accepted: 9 July 2019 / Published: 11 July 2019
PDF Full-text (623 KB) | HTML Full-text | XML Full-text
Abstract
Polycystic ovary syndrome (PCOS) is a complex disorder that results from a combination of multiple factors, including genetic, epigenetic, and environmental influences. Evidence from clinical and preclinical studies indicates that elevated intrauterine androgen levels increase the susceptibility of the female offspring to develop [...] Read more.
Polycystic ovary syndrome (PCOS) is a complex disorder that results from a combination of multiple factors, including genetic, epigenetic, and environmental influences. Evidence from clinical and preclinical studies indicates that elevated intrauterine androgen levels increase the susceptibility of the female offspring to develop the PCOS phenotype. Additionally, early postnatal endocrine and metabolic imbalances may act as a “second-hit”, which, through activational effects, might unmask or amplify the modifications programmed prenatally, thus culminating in the development of adult disease. Animal models provide unparalleled resources to investigate the effects of prenatal exposure to androgen excess and to elucidate the etiology and progression of disease conditions associated with this occurrence, such as PCOS. In sheep, prenatal treatment with testosterone disrupts the developmental trajectory of the fetus, culminating in adult neuroendocrine, ovarian, and metabolic perturbations that closely resemble those seen in women with PCOS. Our longitudinal studies clearly demonstrate that prenatal exposure to testosterone excess affects both the reproductive and the metabolic systems, leading to a self-perpetuating cycle with defects in one system having an impact on the other. These observations in the sheep suggest that intervention strategies targeting multiple organ systems may be required to prevent the progression of developmentally programmed disorders. Full article
(This article belongs to the Special Issue Polycystic Ovary Syndrome)
Figures

Figure 1

Open AccessReview
Steroid Mass Spectrometry for the Diagnosis of PCOS
Med. Sci. 2019, 7(7), 78; https://doi.org/10.3390/medsci7070078
Received: 12 June 2019 / Revised: 8 July 2019 / Accepted: 9 July 2019 / Published: 10 July 2019
PDF Full-text (218 KB) | HTML Full-text | XML Full-text
Abstract
The most appropriate steroids to measure for the diagnosis of hyperandrogenism in polycystic ovary syndrome (PCOS) are still open to debate but should preferably be measured using a high-quality method such as liquid chromatography tandem mass spectrometry (LC-MS/MS). Measurement of testosterone is recommended [...] Read more.
The most appropriate steroids to measure for the diagnosis of hyperandrogenism in polycystic ovary syndrome (PCOS) are still open to debate but should preferably be measured using a high-quality method such as liquid chromatography tandem mass spectrometry (LC-MS/MS). Measurement of testosterone is recommended in all of the current clinical guidelines but other steroids, such as androstenedione and dehydroepiandrosterone sulfate (DHEAS), have also been shown to be useful in diagnosing PCOS and may give additional information on metabolic risk. The 11-oxygenated steroids, and in particular 11KT derived mainly from the adrenal gland, are also increasing in prominence and have been shown to be the dominant androgens in this condition. Polycystic ovary syndrome is a complex syndrome and it is not surprising that each of the clinical phenotypes are associated with different patterns of steroid hormones; it is likely that steroid profiling with LC-MS/MS may be better at identifying hyperandrogensim in each of these phenotypes. Research into PCOS has been hampered by the small sample size of clinical studies previously undertaken and larger studies, preferably using LC-MS/MS profiling of steroids, are needed Full article
(This article belongs to the Special Issue Polycystic Ovary Syndrome)
Open AccessReview
Barriers and Facilitators to the Implementation of Evidence-Based Lifestyle Management in Polycystic Ovary Syndrome: A Narrative Review
Med. Sci. 2019, 7(7), 76; https://doi.org/10.3390/medsci7070076
Received: 30 May 2019 / Revised: 25 June 2019 / Accepted: 26 June 2019 / Published: 27 June 2019
PDF Full-text (688 KB) | HTML Full-text | XML Full-text
Abstract
Polycystic ovary syndrome (PCOS) is a complex condition that involves metabolic, psychological and reproductive complications. Insulin resistance underlies much of the pathophysiology and symptomatology of the condition and contributes to long term complications including cardiovascular disease and diabetes. Women with PCOS are at [...] Read more.
Polycystic ovary syndrome (PCOS) is a complex condition that involves metabolic, psychological and reproductive complications. Insulin resistance underlies much of the pathophysiology and symptomatology of the condition and contributes to long term complications including cardiovascular disease and diabetes. Women with PCOS are at increased risk of obesity which further compounds metabolic, reproductive and psychological risks. Lifestyle interventions including diet, exercise and behavioural management have been shown to improve PCOS presentations across the reproductive, metabolic and psychological spectrum and are recommended as first line treatment for any presentation of PCOS in women with excess weight by the International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018. However, there is a paucity of research on the implementation lifestyle management in women with PCOS by healthcare providers. Limited existing evidence indicates lifestyle management is not consistently provided and not meeting the needs of the patients. In this review, barriers and facilitators to the implementation of evidence-based lifestyle management in reference to PCOS are discussed in the context of a federally-funded health system. This review highlights the need for targeted research on the knowledge and practice of PCOS healthcare providers to best inform implementation strategies for the translation of the PCOS guidelines on lifestyle management in PCOS. Full article
(This article belongs to the Special Issue Polycystic Ovary Syndrome)
Figures

Figure 1

Open AccessReview
A Review of Second- and Third-line Infertility Treatments and Supporting Evidence in Women with Polycystic Ovary Syndrome
Med. Sci. 2019, 7(7), 75; https://doi.org/10.3390/medsci7070075
Received: 14 May 2019 / Revised: 13 June 2019 / Accepted: 20 June 2019 / Published: 26 June 2019
PDF Full-text (217 KB) | HTML Full-text | XML Full-text
Abstract
In clomiphene-citrate-resistant anovulatory women with polycystic ovary syndrome (PCOS) and no other infertility factors, either metformin combined with clomiphene citrate or gonadotrophins could be used as a second-line pharmacological therapy, although gonadotrophins are more effective. Gonadotrophins could also be used as a second-line [...] Read more.
In clomiphene-citrate-resistant anovulatory women with polycystic ovary syndrome (PCOS) and no other infertility factors, either metformin combined with clomiphene citrate or gonadotrophins could be used as a second-line pharmacological therapy, although gonadotrophins are more effective. Gonadotrophins could also be used as a second-line pharmacological therapy in anovulatory women with PCOS and clomiphene-citrate-failure. Laparoscopic ovarian surgery can also be used as a second-line therapy for ovulation induction in anovulatory women with clomiphene-citrate-resistant PCOS and no other infertility factors. The usefulness of letrozole as a second-line pharmacological treatment for ovulation induction in clomiphene-citrate-resistant women with PCOS requires further research. In terms of improving fertility, both pharmacological anti-obesity agents and bariatric surgery should be considered an experimental therapy in anovulatory women with PCOS and no other infertility factors. Where first- or second-line ovulation induction therapies have failed, in vitro fertilization (IVF)/ intracytoplasmic sperm injection (ICSI) could be offered as a third-line therapy in women with PCOS in the absence of an absolute indication for IVF/ICSI. For women with PCOS undergoing IVF/ICSI treatment, the gonadotropin-releasing hormone (GnRH) antagonist protocol is preferred and an elective frozen embryo transfer strategy could be considered. In assisted conception units with sufficient expertise, in-vitro maturation (IVM) of oocytes could be offered to women with PCOS. Full article
(This article belongs to the Special Issue Polycystic Ovary Syndrome)
Open AccessReview
Generational Health Impact of PCOS on Women and Their Children
Med. Sci. 2019, 7(3), 49; https://doi.org/10.3390/medsci7030049
Received: 2 February 2019 / Revised: 8 March 2019 / Accepted: 12 March 2019 / Published: 18 March 2019
PDF Full-text (230 KB) | HTML Full-text | XML Full-text
Abstract
Polycystic ovary syndrome (PCOS) is a metabolic disorder with reproductive consequences. Hence, the synergy of the dual maternal challenges of difficulties with conception, set on a background of metabolic disorder and inflammation, understandably leads to increased obstetric risk for the woman. Furthermore, she [...] Read more.
Polycystic ovary syndrome (PCOS) is a metabolic disorder with reproductive consequences. Hence, the synergy of the dual maternal challenges of difficulties with conception, set on a background of metabolic disorder and inflammation, understandably leads to increased obstetric risk for the woman. Furthermore, she is more likely than her peers to require assistance with conception, either through induction of ovulation with the attendant risk of a multiple gestation, or in vitro fertilization (IVF) with its recognized increased obstetric risk for woman and her child. The increased obstetric risk for a woman with PCOS is manifested with an increased rate of miscarriage, gestational diabetes, hypertensive disorder and premature delivery. These obstetric complications are due to impairment of placental function, systemic inflammation and metabolic disorder and are markers for the woman herself of her predisposition to cardiometabolic disorder in later life. Consequently, it is inevitable that this environment may induce changes in the fetus during pregnancy, leading to an intergenerational risk from maternal PCOS. Full article
(This article belongs to the Special Issue Polycystic Ovary Syndrome)
Med. Sci. EISSN 2076-3271 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top